CN114787144A - 吡啶酮化合物及用于调节蛋白激酶的方法 - Google Patents

吡啶酮化合物及用于调节蛋白激酶的方法 Download PDF

Info

Publication number
CN114787144A
CN114787144A CN202080080953.7A CN202080080953A CN114787144A CN 114787144 A CN114787144 A CN 114787144A CN 202080080953 A CN202080080953 A CN 202080080953A CN 114787144 A CN114787144 A CN 114787144A
Authority
CN
China
Prior art keywords
alkyl
membered
alkylene
cycloalkyl
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080080953.7A
Other languages
English (en)
Chinese (zh)
Inventor
L·巴南
M·布伊
蒋发明
J·毛恩
A·劳布
J·萨尔范特
B·斯潘格勒
K·乔
王勇
许维
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of CN114787144A publication Critical patent/CN114787144A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202080080953.7A 2019-09-26 2020-09-25 吡啶酮化合物及用于调节蛋白激酶的方法 Pending CN114787144A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962906647P 2019-09-26 2019-09-26
US62/906,647 2019-09-26
US202063053530P 2020-07-17 2020-07-17
US63/053,530 2020-07-17
PCT/US2020/052850 WO2021062245A1 (en) 2019-09-26 2020-09-25 Pyridone compounds and methods of use in the modulation of a protein kinase

Publications (1)

Publication Number Publication Date
CN114787144A true CN114787144A (zh) 2022-07-22

Family

ID=72827019

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080080953.7A Pending CN114787144A (zh) 2019-09-26 2020-09-25 吡啶酮化合物及用于调节蛋白激酶的方法

Country Status (8)

Country Link
US (1) US12371428B2 (https=)
EP (1) EP4034532A1 (https=)
JP (1) JP2022551422A (https=)
CN (1) CN114787144A (https=)
AU (1) AU2020351782A1 (https=)
CA (1) CA3155924A1 (https=)
TW (1) TW202126651A (https=)
WO (1) WO2021062245A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117343046A (zh) * 2023-09-25 2024-01-05 辽宁大学 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
WO2024217587A1 (zh) * 2023-04-21 2024-10-24 南京正大天晴制药有限公司 具有axl抑制活性的取代吡嗪化合物
CN118878515A (zh) * 2024-06-19 2024-11-01 河北科技大学 一种取代苯胺嘧啶类化合物及其制备方法和用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022551422A (ja) 2019-09-26 2022-12-09 エグゼリクシス， インコーポレイテッド ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
GB202004960D0 (en) * 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
CA3211063A1 (en) 2021-02-19 2022-08-25 Exelixis, Inc. Pyridone compounds and methods of use
IT202100022682A1 (it) * 2021-09-01 2023-03-01 Luigi Frati Derivati pirimidinici e loro uso nel trattamento di tumori
WO2023114809A1 (en) 2021-12-16 2023-06-22 Kinnate Biopharma Inc. Inhibitors of met kinase
CN114213404B (zh) * 2021-12-27 2024-08-06 武汉九州钰民医药科技有限公司 Vegfr抑制剂替沃扎尼的合成工艺
CN117362275A (zh) * 2022-06-29 2024-01-09 广州百霆医药科技有限公司 一种酪氨酸蛋白激酶抑制剂及其用途
CN121038792A (zh) * 2023-04-17 2025-11-28 赛琳治疗公司 用met激酶抑制剂治疗癌症
WO2024259060A1 (en) * 2023-06-16 2024-12-19 Kinnate Biopharma Inc. Inhibitors of met kinase
WO2025096463A1 (en) * 2023-10-30 2025-05-08 Vibliome Therapeutics, Llc Plk4 modulators

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033196A1 (en) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2008048375A1 (en) * 2006-05-19 2008-04-24 Bayer Healthcare Ag Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
CN101248059A (zh) * 2005-04-27 2008-08-20 安姆根有限公司 作为蛋白激酶抑制剂的取代的酰胺衍生物
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN105408312A (zh) * 2013-07-24 2016-03-16 小野药品工业株式会社 喹啉衍生物
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途
CN113195471A (zh) * 2018-08-27 2021-07-30 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物及其在医药上的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
WO1996003397A1 (en) 1994-07-21 1996-02-08 Akzo Nobel N.V. Cyclic ketone peroxide formulations
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
JP2009539878A (ja) 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
CN102816175B (zh) 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
CN102643268B (zh) 2011-12-30 2014-05-21 沈阳药科大学 喹啉类及噌啉类化合物及其应用
WO2013180949A1 (en) 2012-05-27 2013-12-05 Ning Xi Substituted quinoline compounds and methods of use
CN104072480B (zh) 2013-03-27 2016-12-28 沈阳药科大学 喹啉类化合物及其制备方法和应用
ES2749726T3 (es) 2014-12-25 2020-03-23 Ono Pharmaceutical Co Derivado de quinolina
CN108530426A (zh) 2017-03-02 2018-09-14 沈阳药科大学 含喹喔啉酮的4-苯氧基取代喹啉类化合物及其应用
WO2019080723A1 (zh) 2017-10-26 2019-05-02 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物、其制备方法及其医药用途
CN109896997A (zh) 2017-12-08 2019-06-18 中国药科大学 N－酰基苯胺类c－Met激酶抑制剂的制备方法及其用途
US20210177828A1 (en) 2018-01-17 2021-06-17 Nanjing Transthera Biosciences Co., Ltd. Tam family kinase /and csf1r kinase inhibitor and use thereof
ES2985569T3 (es) 2018-08-24 2024-11-06 Transthera Sciences Nanjing Inc Nuevo inhibidor de derivado de quinolina
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
JP7542613B2 (ja) * 2019-09-06 2024-08-30 上海 インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ Ａｘｌとｃ－Ｍｅｔキナーゼ阻害活性を有する化合物およびその製造と使用
JP2022551422A (ja) 2019-09-26 2022-12-09 エグゼリクシス， インコーポレイテッド ピリドン化合物およびタンパク質キナーゼの調節における使用の方法
JP2023514725A (ja) 2020-02-24 2023-04-07 エグゼリクシス， インコーポレイテッド 化合物および使用方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101248059A (zh) * 2005-04-27 2008-08-20 安姆根有限公司 作为蛋白激酶抑制剂的取代的酰胺衍生物
WO2007033196A1 (en) * 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
WO2008048375A1 (en) * 2006-05-19 2008-04-24 Bayer Healthcare Ag Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
CN103958497A (zh) * 2011-11-14 2014-07-30 赛福伦公司 作为AXL和c-MET激酶抑制剂的尿嘧啶衍生物
CN105408312A (zh) * 2013-07-24 2016-03-16 小野药品工业株式会社 喹啉衍生物
CN113195471A (zh) * 2018-08-27 2021-07-30 北京越之康泰生物医药科技有限公司 多取代吡啶酮类衍生物及其在医药上的应用
CN110330479A (zh) * 2019-07-19 2019-10-15 南京华威医药科技集团有限公司 一种用作axl抑制剂的抗肿瘤化合物及其用途

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
JU LIU，ET AL.: ""Design, synthesis and biological evaluation of novel 4-phenoxyquinoline derivatives containing 3-oxo-3, 4-dihydroquinoxaline moiety as c-Met kinase inhibitors"", 《BIOORGANIC & MEDICINAL CHEMISTRY》, vol. 25, pages 4475 - 4486, XP085133591, DOI: 10.1016/j.bmc.2017.06.037 *
QIDONG TANG，ET AL.: ""Design, synthesis, and structureeactivity relationships of novel 6, 7- disubstituted-4-phenoxyquinoline derivatives as potential antitumor agents"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 69, pages 77 - 89 *
QIDONG TANG，ET AL.: ""Synthesis and antiproliferative activity of 6, 7-disubstituted-4-phenoxyquinoline derivatives bearing the 1, 8-naphthyridin-2-one moiety"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 158, pages 201 - 213, XP055748184, DOI: 10.1016/j.ejmech.2018.08.066 *
ROGER CLARK，ET AL.: ""A flexible high content imaging assay for profiling macrophage efferocytosis"", 《JOURNAL OF IMMUNOLOGICAL METHODS》, vol. 473, pages 1 - 11 *
SAI LI，ET AL.: ""Design，synthesis and antitumour activity of bisquinoline derivatives connected by 4-oxy-3-fluoroaniline moiety"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 64, pages 62 - 73, XP028566334, DOI: 10.1016/j.ejmech.2013.04.001 *
WEI ZHANG，ET AL.: ""Discovery of Novel c-Met Inhibitors Bearing a 3-Carboxyl Piperidin-2-one Scaffold"", 《MOLECULES》, vol. 19, pages 2655 - 2673, XP055460997, DOI: 10.3390/molecules19022655 *
WEI ZHANG，ET AL.: ""Discovery of novel type II c-Met inhibitors based on BMS-777607"", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, vol. 80, pages 254 - 266 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217587A1 (zh) * 2023-04-21 2024-10-24 南京正大天晴制药有限公司 具有axl抑制活性的取代吡嗪化合物
CN117343046A (zh) * 2023-09-25 2024-01-05 辽宁大学 一种新型3-氧代-4-取代芳基-3,4-二氢吡嗪-2-甲酰胺类化合物及其应用
CN118878515A (zh) * 2024-06-19 2024-11-01 河北科技大学 一种取代苯胺嘧啶类化合物及其制备方法和用途
CN118878515B (zh) * 2024-06-19 2025-10-28 河北科技大学 一种取代苯胺嘧啶类化合物及其制备方法和用途

Also Published As

Publication number Publication date
US12371428B2 (en) 2025-07-29
EP4034532A1 (en) 2022-08-03
US20220315579A1 (en) 2022-10-06
CA3155924A1 (en) 2021-04-01
WO2021062245A1 (en) 2021-04-01
TW202126651A (zh) 2021-07-16
AU2020351782A1 (en) 2022-04-21
JP2022551422A (ja) 2022-12-09

Similar Documents

Publication Publication Date Title
CN114787144A (zh) 吡啶酮化合物及用于调节蛋白激酶的方法
CN109476641B (zh) Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
JP6026427B2 (ja) 置換６，６−縮合窒素複素環化合物及びその使用
CN107108512B (zh) 治疗性化合物及其用途
JP6771464B2 (ja) Ｃｂｐおよび／またはｅｐ３００インヒビターとしての、４，５，６，７−テトラヒドロ−１ｈ−ピラゾロ［４，３−ｃ］ピリジン−３−アミン化合物
JP5406039B2 (ja) タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
KR101530117B1 (ko) 야누스 키나제 억제제 화합물 및 방법
JP2023521633A (ja) 化合物、医薬組成物、ならびに化合物の調製方法及び使用方法
JP2023519430A (ja) Ｍｙｔ１阻害剤の使用方法
CN107912040A (zh) 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
EP4294804B1 (en) Pyridone compounds and methods of use
JP2025517733A (ja) ヘテロアレーン、それを含む医薬組成物、及びその使用方法
US20230151003A1 (en) Compounds and methods of use
CN117440951A (zh) 吡啶酮化合物和使用方法
HK40079390A (en) Substituted pyrrolopyrdines as inhibitors of bromodomain
HK40079501A (en) Heterocyclic inhibitors of cbp/ep300 and their use in treatment of cancer
EA050141B1 (ru) Соединения, фармацевтические композиции, а также способы получения соединений и их применения
HK40005957B (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
HK40005957A (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
HK1243073B (zh) 治療性化合物及其用途
HK1248695B (zh) 用作cbp和/或ep300抑制劑的4，5，6，7-四氫-1h-吡唑並[4，3-c]吡啶-3-胺化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220722